Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities?

Neuropsychopharmacology

Volumn 19, Issue 5, 1998, Pages 434-444

  Radant, Allen D ^a,c,d   Bowdle, T Andrew ^b   Cowley, Deborah S ^a   Kharasch, Evan D ^b,c   Roy Byrne, Peter P ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Veterans Affairs Puget Sound   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Glutamate; Ketamine; NMDA receptors; Oculomotor; Schizophrenia

Indexed keywords

GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO;

ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; EYE MOVEMENT CONTROL; HUMAN; HUMAN EXPERIMENT; INTELLIGENCE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; NYSTAGMUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL; RECOGNITION; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE;

ADULT; AFFECT; COGNITION; EXCITATORY AMINO ACID ANTAGONISTS; EYE MOVEMENTS; HUMANS; KETAMINE; MALE; MEMORY; RECEPTORS, N-METHYL-D-ASPARTATE; SINGLE-BLIND METHOD;

EID: 0032210874     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00030-X     Document Type: Article

References (52)

1. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney W.E. Jr., Jones E.G. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci. 16:1996;19-30.
2. Bartha R., Williamson P.C., Drost D.J., Malla A., Carr T.J., Cortese L., Canaran G., Rylett R.J., Neufeld R.W. Measurement of glutamate and glutamine in the medial prefrontal cortex of never treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiat. 54:1997;959-965.
3. Benes F.M., McSparren J., San-Giovanni J.P., Vincent S.L. Deficits in small interneurons in cingulate cortex of schizophrenic and schizoaffective patients. Arch Gen Psychiat. 48:1991;996-1001.
4. Benes F.M., Sorensen I., Vincent S.L., Bird E.D., Sathi M. Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain. Cereb Cortex. 2:1992;502-512.
5. Benes F.M. Altered glutamatergic and GABAergic mechanisms in the cingulate cortex of the schizophrenic brain. Arch Gen Psychiat. 52:1995;1015-1018.
6. Benton A.L., Hamsher K., Varney N.R., Spreen O. Contributions to Neuropsychological Assessment. 1983;Oxford University Press, New York.
7. Bosco G., Casabona A., Perciavalle V. Non-N-methyl-D-Aspartate receptors mediate neocerebellar excitation at accessory oculomotor nuclei synapses of the rat. Arch Ital Biol. 132:1994;215-227.
8. Brier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiat. 154:1997;805-811.
9. Byrd L.D., Standis L.J., Howell L.L. Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs. Eur J Pharmacol. 144:1987;331-341.
10. Clementz B.A., McDowell J.E., Zisook S. Saccadic system functioning among schizophrenia patients and their first-degree biological relatives. J Abnorm Psychol. 103:1994;277-287.
11. Clementz B.A., McDowell J.E. Smooth pursuit in schizophrenia. Abnormalities of open and closed-loop responses. Psychophysiology. 31:1994;79-86.
12. Conti F., Minelli A., DeBiasi S., Melone M. Neuronal and glial localization of NMDA receptors in the cerebral cortex. Mol Neurobiol. 13:1997;1-18.
13. Corssen G., Domino E.F. Dissociative anesthesia. Further pharmacologic studies and first clinical experience with phencyclidine derivative CI-581. Anesth Analges. 45:1966;29-40.
14. Domino E.F., Domino S.E., Smith R.E., Domino L.E., Goulet J.R., Domino K.E., Zsigmond E.K. Ketamine kinetics in unmedicated and diazepam-premedicated subjects. Clin Pharmacol Ther. 36:1984;645-653.
15. Fukushima J., Morita N., Fukushima K., Chiba T., Tanaka S., Yamashita I. Voluntary control of saccadic eye movements in patients with schizophrenic and affective disorders. J Psychiat Res. 24:1990;9-24.
16. Funahashi S., Chafee M.V., Goldman-Rakic P.S. Prefrontal neuronal activity in rhesus monkeys performing a delayed antisaccade task. Nature. 365:1993;753-756.
17. Ginski M.J., Witkin J.M. Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists. Psychopharmacol Berl. 114:1994;573-582.
18. Glass P.S., Jacobs J.R., Smith R.L., Ginsberg B., Quill T.J., Bai S.A., Reves J.G. Pharmacokinetic model-driven infusion of fentanyl. Assessment of accuracy Anesthesiology. 73:1990;1082-1090.
19. Godaux E., Cheron G., Mettens P. Ketamine induces failure of the oculomotor neural integrator in the cat. Neurosci Lett. 116:1990;162-167.
20. Grawe R.W., Levander S. Smooth pursuit eye movements and neuropsychological impairments in schizophrenia. Acta Psychiat Scand. 92:1995;108-114.
21. Grove W.M., Clementz B.A., Iacono W.G., Katsanis J. Smooth pursuit ocular motor dysfunction in schizophrenia. Evidence for a major gene Am J Psychiat. 149:1992;1362-1368.
22. 11C] ketamine in the rhesus monkey studied by positron emission tomography, PET. Nucl Med Biol. 21:1994;927-934.
23. Hartvig P., Valtysson J., Linder K., Kristensen J., Karlsten R., Gustafsson L.L., Persson J., Svensson J.O., Oye I., Antoni G., Westerberg G., Langstrom B. Central nervous system effects of subdissociative doses of (S) ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther. 58:1995;165-173.
24. Holzman P.S., Kringlen E., Matthysse S., Flanagan S.D., Lipton R.B., Cramer G., Levin S., Lange K., Levy D.L. A single dominant gene can account for eye-tracking dysfunctions and schizophrenia in offspring of discordant twins. Arch Gen Psychiat. 45:1988;641-647.
25. Ishimaru M., Kurumaji A., Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics. Evidence for glutamate hypothesis Biol Psychiat. 35:1994;84-95.
26. Jansen K.L., Dragunow M., Faull R.L., Leslie R.A. Autoradiographic visualization of [3H]DTG binding to sigma receptors, [3H]TCP binding sties, and L-[3H]glutamate binding to NMDA receptors in human cerebellum. Neurosci Lett. 125:1991;143-146.
27. Kharasch E.D., Labroo R. Metabolism of ketamine stereoisomers by human liver microsomes. Anesthesiology. 77:1992;1201-1207.
28. Kruger-Theimer E. Continuous intravenous infusion and multicompartment accumulation. Eur J Pharmacol. 4:1968;317-324.
29. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charnew D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiat. 51:1994;199-214.
30. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
31. LaPorte D.J., Lahti A.C., Koffel B., Tamminga C.A. Absence of ketamine effects on memory and other cognitive functions in schizophrenia patients. J Psychiat. 30:1996;321-330.
32. Lear E., Suntay R., Pallin I.M., Chiron A.E. Cyclohexamine (CI-400). A new intravenous agent. Anesthesiology. 20:1959;330-334.
33. Litman R.E., Hommer D.W., Radant A., Clem T., Pickar D. Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia. Schizophr Res. 12:1994;107-120.
34. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug - sernyl. Arch Neurlol Psychiat. 81:1959;363-369.
35. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Brier A. NMDA receptor function and human cognition. The effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307.
36. Mettens P., Cheron G., Godaux E. Involvement of the N-methyl-D-aspartate receptors of the vestibular nucleus in the gazeholding system of the cat. Neurosci Lett. 174:1994;209-212.
37. O'Driscoll G.A., Alpert N.M., Matthysse S.W., Levy D.L., Rauch S.L., Holzman P.S. Functional neuroanatomy of antisaccade eye movements investigated with positron emission tomography. Proc Natl Acad Sci USA. 92:1995;925-929.
38. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiat. 52:1995;998-1007.
39. Radant A.D., Hommer D.W. A quantitative analysis of saccades and smooth pursuit during visual pursuit tracking. A comparison of schizophrenics with normals and substance abusing controls Schizophr Res. 6:1992;225-235.
40. Rashbass C. The relationship between saccadic and smooth pursuit tracking eye movements. J Physiol (Lond). 159:1961;326-338.
41. Ross D.E., Thaker G.K., Holcomb H.H., Cascella N.G., Medoff D.R., Tamminga C.A. Abnormal smooth pursuit eye movements in schizophrenic patients are associated with cerebral glucose metabolism in oculomotor regions. Psychiat Res. 58:1995;53-67.
42. Ross R.G., Hommer D., Breiger D., Varley C., Radant A. Eye movement task related to frontal lobe functioning in children with attention deficit disorder. J Am Acad Child Adolesc Psychiat. 33:1994;869-874.
43. Roy-Byrne P., Radant A., Wingerson D., Cowley D.S. Human oculomotor function. Reliability and diurnal variation Biol Psych. 38:1995;92-97.
44. Roy-Byrne P.P., Uhde T.W., Holcomb H.H., King A.K., Thompson K., Weingartner H. Effects of diazepam on cognitive processess in normal subjects. Psychopharmacology. 91:1987;30-33.
45. Schreiber H., Rothmeier J., Becker W., Jrugens R., Born J., Stolz-Born G., Westphal K.P., Kornhuber H.H. Comparative assessment of saccadic eye movements, psychomotor and cognitive performance in schizophrenics, their first-degree relatives and control subjects. Acta Psychiat Scand. 91:1995;195-201.
46. Schuttler J., Kloos S., Schwilden H., Stoeckel H. Total intravenous anaesthesia with propofol and alfentanil by computer-assisted infusion. Anaesthesia. 43:1988;2-7.
47. Shafer S.L., Vervel J.R., Aziz N., Scott J.C. Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. Anesthesiology. 73:1990;1091-1102.
48. Simpson M.D., Slater P., Royston M.C., Deakin J.F. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr Res. 6:1991;41-48.
49. Ulas J., Weihmuller F.B., Brunner L.C., Joyce J.N., Marshall J.F., Cotman C.W. Selective increase of NMDA sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients. An autoradiographic study J Neurosci. 14:1994;6317-6324.
50. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats. Modulation by dopamine. J Neurosci. 16:1996;373-379.
51. Vollenweider F.X., Leenders K.L., Oye I., Hell D., Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produces by (S) and (R) ketamine in healthy volunteers using positron emission tomography (PET). Eur J Neuropsychopharmacol. 7:1997;25-38.
52. Watanabe M., Mishina M., Inoue Y. Distinct distributions of five NMDA receptor channel subunit mRNAs in the brainstem. J Comp Neurol. 343:1994;510-531.